Patent · US Active

2,3,5-trimelthyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders

US11174212B2 · kind B2 · utility

3Cited by

9References

32Claims

0Family size

Assignee

PTC THERAPEUTICS, INC. · US

Inventors

Andrew W. Hinman · San Francisco, US
Charles R. Holst · San Jose, US
Angela Minnella · South Plainfield, US
Paul Mollard · Domène, FR
Sean Pintchovski · South Plainfield, US
Jeffrey K. Trimmer · Redwood City, US
Eric Torrey · South Plainfield, US

Key dates

Filing date	Mar 30, 2021
Grant date	Nov 16, 2021
Priority date	—
Expiry date	Mar 30, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein are methods of treating or suppressing a disorder selected from the group consisting of α-synucleinopathies, tauopathies, ALS, traumatic brain injury, and ischemic-reperfusion related injuries.ury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: or the hydroquinone form thereof; or a solvate or hydrate thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.